April 30, 2018 / 8:19 PM / 3 months ago

BRIEF-Novartis Says Receives FDA Approval Of Tafinlar + Mekinist For Adjuvant Treatment Of Braf V600-Mutant Melanoma

April 30 (Reuters) - Novartis AG:

* RECEIVES FDA APPROVAL OF TAFINLAR + MEKINIST FOR ADJUVANT TREATMENT OF BRAF V600-MUTANT MELANOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below